Labcorp Extends Receivables Facility to 2029, Boosts Capacity by $125 Million
LH sits 29% above its 52-week low of $209.375.
Summary
Labcorp extended its receivables purchase agreement to 2029 and increased its accordion facility by $125 million, enhancing long-term liquidity and financial flexibility.
Key Events · Financing and Capital Events · LH
-
Receivables Facility Extended
The scheduled termination date of the receivables purchase agreement was extended from August 23, 2027, to January 26, 2029.
-
Accordion Facility Increased
A committed $125 million accordion facility was added, raising the total facility limit from $700 million to $825 million.
-
SOFR Adjustment Removed
A 0.10% SOFR adjustment was removed from capital accruing yield, potentially reducing financing costs.
-
Default Threshold Raised
The Threshold Amount for certain indebtedness default triggers was increased from $200 million to $250 million.
Analysis · LH · Industrial Applications And Services
Labcorp Holdings Inc. has amended its receivables purchase agreement, extending the scheduled termination date by over two years to January 26, 2029. This extension provides enhanced long-term liquidity and financial stability. Additionally, the company added a committed $125 million accordion facility, increasing the total facility limit from $700 million to $825 million, which significantly expands its available capital. The removal of a 0.10% SOFR adjustment also slightly reduces financing costs. These changes collectively improve Labcorp's financial flexibility and access to capital.
At the time of this filing, LH was trading at $269.81 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $22.4B. The 52-week trading range was $209.38 to $293.72. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.